Published in J Clin Oncol on April 12, 2010
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
Chemotherapy advances in small-cell lung cancer. J Thorac Dis (2013) 1.08
Therapeutic procedure in small cell lung cancer. J Thorac Dis (2013) 1.06
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol (2016) 1.03
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Oncogene (2013) 0.94
Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biol Ther (2012) 0.86
C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin. Clin Med Insights Oncol (2013) 0.83
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol (2010) 0.83
The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients. Invest New Drugs (2015) 0.82
Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer. Clin Med Insights Oncol (2011) 0.82
Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride. Clin Med Insights Oncol (2011) 0.78
Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma. Gastroenterol Res Pract (2015) 0.77
Chemotherapy for small cell lung cancer: a comprehensive review. Oncol Rev (2012) 0.75
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. BMC Cancer (2016) 0.75
Efficacy of different monotherapies in second-line treatment for small cell lung cancer: a meta-analysis of randomized controlled trials. Int J Clin Exp Med (2015) 0.75
Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients. Sci Rep (2016) 0.75
Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. J Transl Med (2016) 0.75
Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer. Drug Des Devel Ther (2013) 0.75
Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma. Mol Clin Oncol (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol (2012) 5.16
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol (2012) 3.28
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett (2004) 3.17
A feasibility study evaluating the role of cerebral oximetry in predicting return of spontaneous circulation in cardiac arrest. Resuscitation (2012) 3.00
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol (2007) 2.99
Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA (2004) 2.99
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol (2007) 2.93
Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol (2010) 2.84
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev (2003) 2.81
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol (2008) 2.78
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol (2003) 2.69
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol (2004) 2.55
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol (2012) 2.52
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol (2012) 2.44
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res (2003) 2.39
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol (2008) 2.32
Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life. J Clin Oncol (2007) 2.31
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol (2013) 2.27
The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev (2004) 2.23
Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol (2013) 2.22
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov (2011) 2.22
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res (2010) 2.20
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev (2002) 2.08
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol (2005) 2.07
Early effect of tidal volume on lung injury biomarkers in surgical patients with healthy lungs. Anesthesiology (2014) 2.06
c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res (2007) 2.06
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03
Identifying melanomas in primary care: can we do better? BMJ (2012) 2.01
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2011) 1.99
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol (2009) 1.95
Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol (2012) 1.91
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res (2002) 1.84
Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol (2010) 1.84
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res (2002) 1.82
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood (2004) 1.81
Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J (2012) 1.80
Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst (2013) 1.80
Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res (2003) 1.79
Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol (2007) 1.79
Are anonymous evaluations a better assessment of faculty teaching performance? A comparative analysis of open and anonymous evaluation processes. Fam Med (2005) 1.75
Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. Clin Cancer Res (2004) 1.69
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog (2008) 1.68
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res (2006) 1.64
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol (2011) 1.63
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res (2006) 1.61
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res (2008) 1.60
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res (2007) 1.59
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol (2006) 1.55
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem (2007) 1.53
Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review. Cancer (2004) 1.53
Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.52
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg (2012) 1.51
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res (2005) 1.50
c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep (2007) 1.50
Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys (2002) 1.49
Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J Clin Oncol (2012) 1.48
Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol (2002) 1.47
The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg (2010) 1.46
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem (2001) 1.45
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal (2014) 1.44
Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone. Transl Res (2009) 1.42
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother (2014) 1.42
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol (2008) 1.41
Case report of rituximab-induced thrombocytopenia. Am J Hematol (2004) 1.41
Fyn: a novel molecular target in cancer. Cancer (2010) 1.40
Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol (2010) 1.37
Collision tumor versus multiphenotypic differentiation: a case of carcinoma with features of colonic and lung primary tumors. Anticancer Res (2009) 1.35
Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol (2012) 1.34
Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys (2008) 1.33